Jennifer K. Simpson
2021 - Panbela Therapeutics
In 2021, Jennifer K. Simpson earned a total compensation of $1.2M as President and Chief Executive Officer at Panbela Therapeutics, a 31% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $182,422 |
|---|---|
| Option Awards | $537,702 |
| Salary | $476,609 |
| Total | $1,196,733 |
Simpson received $537.7K in option awards, accounting for 45% of the total pay in 2021.
Simpson also received $182.4K in non-equity incentive plan and $476.6K in salary.
Rankings
In 2021, Jennifer K. Simpson's compensation ranked 8,126th out of 12,415 executives tracked by ExecPay. In other words, Simpson earned more than 34.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,126 out of 12,415 | 35th |
Division Manufacturing | 3,591 out of 5,505 | 35th |
Major group Chemicals And Allied Products | 1,595 out of 2,375 | 33rd |
Industry group Drugs | 1,419 out of 2,096 | 32nd |
Industry Pharmaceutical Preparations | 1,054 out of 1,546 | 32nd |
Source: SEC filing on April 29, 2022.
Simpson's colleagues
We found two more compensation records of executives who worked with Jennifer K. Simpson at Panbela Therapeutics in 2021.
News
Panbela Therapeutics CEO Jennifer Simpson's 2021 pay jumps 372% to $1.2M
April 29, 2022
Panbela Therapeutics CEO Jennifer Simpson's 2020 pay jumps 62% to $1.7M
April 15, 2021
Delcath Systems CEO Gerard Michel's 2020 pay jumps 150% to $5.8M
April 7, 2021
Delcath Systems CEO Jennifer Simpson's 2019 pay jumps 97% to $1.1M
November 2, 2020
Delcath Systems CEO Jennifer Simpson's 2018 pay slips 11% to $542K
August 19, 2019